Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. It operates through the following segments: Branded Pharmaceuticals, Contract Manufacturing, Obesity and Weight Management, Europe, and Specialty Products. The Branded Pharmaceuticals segment involves the sale of branded pharmaceutical products. The Contract Manufacturing segment involves the contract manufacturing of pharmaceutical, food and animal nutrition products on behalf of domestic and international pharmaceutical and food companies. The Obesity and Weight Management segment is involved in the manufacture and sale of a range of products across a number of channels including FMCG, pharmacy, health food stores and online. The Europe segment is involved in the manufacture and sale of products within Europe. The Specialty Products segment involves in the sale of human and animal nutrition products, incorporating the sale of ingredients and additives for use in the pharmaceutical and food industries. The company was founded in 1997 and is headquartered in Melbourne, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company